Gunnar Birgegard

List of Publications by Year
in descending order

74 papers	5,198 citations	201385 27 h-index	85405 71 g-index
77 all docs	77 docs citations	77 times ranked	4295 citing authors

#	Article	IF	Citations
1	Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood, 2007, 110, 1092-1097.	0.6	808
2	The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. European Journal of Cancer, 2004, 40, 2293-2306.	1.3	749
3	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. Journal of Clinical Oncology, 2011, 29, 761-770.	0.8	724
4	European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. Journal of Crohn's and Colitis, 2015, 9, 211-222.	0.6	425
5	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients. Blood, 2011, 118, 401-408.	0.6	280
6	Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, 2009, 113, 4829-4833.	0.6	229
7	Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms. Journal of Clinical Oncology, 2011, 29, 2410-2415.	0.8	215
8	Cancer-Related Anemia: Pathogenesis, Prevalence and Treatment. Oncology, 2005, 68, 3-11.	0.9	156
9	A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. British Journal of Haematology, 2010, 148, 961-963.	1.2	144
10	A phase II trial of pegylated interferon Î±-2b therapy for polycythemia vera and essential thrombocythemia. Cancer, 2006, 106, 2397-2405.	2.0	104
11	Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. European Journal of Haematology, 2006, 77, 378-386.	1.1	97
12	New Guidelines on Anaemia Management in Patients with Cancer: How Do These Affect Clinical Practice?. Oncology, 2005, 69, 17-21.	0.9	90
13	Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood, 2014, 123, 3803-3810.	0.6	79
14	Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment. British Journal of Haematology, 1992, 81, 603-606.	1.2	65
15	Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica, 2004, 89, 520-7.	1.7	64
16	Serum erythropoietin in rheumatoid arthritis and other inflammatory arthritides: relationship to anaemia and the effect of antiâ€inflammatory treatment. British Journal of Haematology, 1987, 65, 479-483.	1.2	62
17	Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. Haematologica, 2018, 103, 51-60.	1.7	58
18	Independent Risk Factors for Anemia in Cancer Patients Receiving Chemotherapy: Results from the European Cancer Anaemia Survey. Oncology, 2006, 70, 34-48.	0.9	55

#	Article	IF	Citations
19	A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The <scp>PROFOUND</scp> Trial. Pharmacotherapy, 2016, 36, 402-414.	1.2	48
20	Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica, 2017, 102, 85-93.	1.7	46
21	Serum Ferritin Levels in Male Blood Donors. Vox Sanguinis, 1978, 34, 65-70.	0.7	36
22	Change in student attitudes to medical school after the introduction of problem-based learning in spite of low ratings. Medical Education, 1998, 32, 46-49.	1.1	35
23	Cerebrospinal fluid ferritin in patients with cerebral infarction or bleeding. Acta Neurologica Scandinavica, 1980, 61, 384-392.	1.0	34
24	Serum Ferritin and Erythrocyte 2,3â€ÐPG during Quantitated Phlebotomy and Iron Treatment. Scandinavian Journal of Haematology, 1977, 19, 327-333.	0.0	33
25	Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Medical Oncology, 2014, 31, 302.	1.2	32
26	Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study. Leukemia Research, 2013, 37, 162-168.	0.4	29
27	Long-term management of thrombocytosis in essential thrombocythaemia. Annals of Hematology, 2009, 88, 1-10.	0.8	28
28	Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica, 2006, 91, 1281-2.	1.7	26
29	CaphosolÂ® mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation. A pilot study. European Journal of Oncology Nursing, 2015, 19, 50-53.	0.9	25
30	Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up. Hematology, 2013, 18, 8-13.	0.7	23
31	Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study. Haematologica, 2014, 99, 679-687.	1.7	23
32	Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group. European Journal of Haematology, 2019, 102, 235-240.	1.1	21
33	Serum Ferritin during Inflammation A Study on Myocardial Infarction. Acta Medica Scandinavica, 1979, 206, 361-366.	0.0	20
34	Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Medical Oncology, 2007, 24, 63-70.	1.2	19
35	Serum Ferritin in the Regulation of Iron Therapy in Blood Donors. Vox Sanguinis, 1980, 38, 29-35.	0.7	18
36	Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Leukemia Research, 2017, 63, 34-40.	0.4	18

#	Article	IF	Citations
37	Managing anemia in lymphoma and multiple myeloma. Therapeutics and Clinical Risk Management, 2008, Volume 4, 527-539.	0.9	17
38	Serum Ferritin in Ethiopian Mothers and their Newborn Infants. Relation to Iron Intake and Socioâ€Economic Conditions. Scandinavian Journal of Haematology, 1981, 27, 247-252.	0.0	17
39	Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. Lancet Haematology,the, 2021, 8, e658-e665.	2.2	17
40	The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group. Cancer, 2016, 122, 1888-1896.	2.0	16
41	Improving Awareness of the Psychosocial Needs of the Patienta Training Course for Experienced Cancer Doctors. Acta OncolÃ³gica, 1996, 35, 246-247.	0.8	15
42	Anagrelide Treatment in Myeloproliferative Disorders. Seminars in Thrombosis and Hemostasis, 2006, 32, 260-266.	1.5	15
43	Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged >80ÂYears: An Interim Analysis of the EXELS Study. Clinical Drug Investigation, 2013, 33, 55-63.	1.1	15
44	Improved Care of Patients with Small Cell Lung Cancer Nutritional and Quality of Life Aspects. Acta OncolÃ³gica, 1992, 31, 823-831.	0.8	14
45	Advances and challenges in the management of essential thrombocythemia. Therapeutic Advances in Hematology, 2015, 6, 142-156.	1.1	13
46	The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia. Current Hematologic Malignancy Reports, 2016, 11, 348-355.	1.2	13
47	Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study. Leukemia Research, 2018, 74, 105-109.	0.4	13
48	Physiological response to phlebotomies for autologous transfusion at elective hip-joint surgery. European Journal of Haematology, 2009, 46, 136-139.	1.1	10
49	Does anything work for anaemia in myelofibrosis?. Best Practice and Research in Clinical Haematology, 2014, 27, 175-185.	0.7	10
50	Preoperative autologous donation of 6 units of blood during rh-EPO treatment. Canadian Journal of Anaesthesia, 1997, 44, 1315-1318.	0.7	9
51	Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). Blood, 2013, 122, 4087-4087.	0.6	9
52	Regulation of Iron Therapy by S-Ferritin Estimations in Patients on Chronic Hemodialysis. Scandinavian Journal of Urology and Nephrology, 1981, 15, 69-72.	1.4	7
53	Myeloproliferative Neoplasm Quality Of Life (MPN-QOL) Study Group: Observational Study Of Quality Of Life and Symptomatic Response In Myelofibrosis Patients Receiving Undergoing Treatment With Conventional Therapy, The Measures Trial and Allogeneic Stem Cell Transplant, The Symptoms Trial. Blood, 2013, 122, 4090-4090.	0.6	7
54	Intravenous Ferric Carboxymaltose As Sole Anemia Therapy In Patients With Lymphoid Malignancies, Chemotherapy-Induced Anemia and Functional Iron Deficiency. Blood, 2013, 122, 3439-3439.	0.6	6

#	Article	IF	Citations
55	Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response. Blood, 2013, 122, 4067-4067.	0.6	6
56	Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). Blood, 2013, 122, 4088-4088.	0.6	6
57	TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders. International Journal of Medical Sciences, 2008, 5, 87-91.	1.1	6
58	Essential thrombocythaemia treatment options: addressing patientâ€šspecific needs. European Journal of Haematology, 2007, 79, 27-31.	1.1	5
59	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): An International Prospective Validation Trial In 402 Patients. Blood, 2010, 116, 4095-4095.	0.6	5
60	Pharmacological management of essential thrombocythemia. Expert Opinion on Pharmacotherapy, 2013, 14, 1295-1306.	0.9	4
61	The Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs),. Blood, 2011, 118, 3839-3839.	0.6	4
62	JAK2 V617F as a Marker for Long-Term Disease Progression and Mortality in Polycythemia Vera and its Role in Economic Modeling. Journal of Health Economics and Outcomes Research, 2020, 7, 61-70.	0.6	4
63	Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients. Blood, 2012, 120, 1726-1726.	0.6	4
64	Evaluation of beta globin mRNA as an early marker of haemoglobin response to epoetin treatment. Medical Oncology, 2007, 24, 318-322.	1.2	3
65	Unexpected 5 Year Survival Benefit in Patients Given Oral Cryotherapy During Conditioning for Stem Cell Transplantation. A Prospective Randomized Study. Blood, 2011, 118, 4559-4559.	0.6	2
66	The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients. Blood, 2012, 120, 1731-1731.	0.6	2
67	CIRCADIAN VARIATION OF GRANULOCYTE COLONY-STIMULATING FACTOR LEVELS IN MAN. British Journal of Haematology, 2000, 108, 661-661.	1.2	1
68	SUBCELLULAR CHARACTERIZATION OF THE TRANSFERRINâ€TRANSFERRIN RECEPTOR AND IRON ACCUMULATING SYSTEM OF ESTABLISHED HUMAN ERYTHROID AND MONOBLASTOID TUMOUR CELL LINES. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section A, Pathology, 1986, 94A, 245-252.	0.3	1
69	The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe. HemaSphere, 2019, 3, e291.	1.2	1
70	Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial. Blood, 2018, 132, 1762-1762.	0.6	1
71	New perspectives in managing myeloproliferative disorders: focus on the patient. Hematological Oncology, 2009, 27, 5-7.	0.8	0
72	Functional Iron Deficiency Effectively Overcome by Adjuvant IV Iron during Epoetin Treatment.. Blood, 2006, 108, 3725-3725.	0.6	0

#	Article	IF	Citations
73	Evaluation of beta Globin mRNA as an Early Marker of Hb Response to Epoetin Treatment.. Blood, 2006, 108, 3750-3750.	0.6	0
74	Prospective Validation of the Swedish Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Swedish) In 114 MPN Patients. Blood, 2010, 116, 5053-5053.	0.6	0